Oculis Holding AG - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OCS Nasdaq 2830 oculis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Oculis Holding AG

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - Aug 24th, 2026 2:00 am
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Aug 14th, 2026 2:05 pm
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Aug 14th, 2026 7:55 am
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor - Aug 10th, 2026 2:45 am
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - Aug 10th, 2026 1:30 am
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2026 8:35 pm
Oculis Reports Q2 2026 Financial Results and Provides Company Update - Aug 6th, 2026 2:05 pm
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Aug 3rd, 2026 2:00 am
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Jul 2nd, 2026 2:00 am
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - Jun 11th, 2026 2:00 am
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - Jun 9th, 2026 2:00 am
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - Jun 8th, 2026 1:25 pm